Blood: Prognosis for patients with Burkitt lymphoma over the past decade.

!----: In adult BL, 19% of patients have central nervous system conditions, 14% of all patients are primary and refractive diseases, TRM is 10%, and PFS is 64% in 3 yearsThe researchers identified four clinical factors that had independent predictive significance for the patient's prognosis (age : 40 years, LDH sgt; 3x, ECOG PS 2 and CNS immersion)Abstract: Evens et alsurveyed adult patients with initial treatment of Burkitt lymphoma (BL) at 30 cancer centers in the United States from 2009 to 2018The factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated through the single-variable and multivariate Cox modelsIn 641 BL patients, the underlying characteristics included: median age 47 years old, HIV-positive rate of 22%, 23% of patients ECOG performance status (PS) 2-3 points, 43% of patients had 1 lymph node invasion, 78% of patients were advanced and central nervous system (CNS) tired rate of 19%Treatment-related mortality (TRM) was 10% and the most common causes of death were sepsis, gastrointestinal bleeding/perforation and respiratory failureThe median follow-up was 45 months, and the 3-year PFS and OS rates were 64% and 70%, respectively, independent of HIV statusThe use of rituximatoma therapy has a higher survival rate than patients who did not use rituximatomatherapy (3 years PFS: 67% vs 38%, OS: 72% vs 44%, p-lt;0.001) and is independent of the method of administration (inpatient/outpatient)Patients treated in academic centres had a better prognosis than patients treated in community centres (3 years PFS: 67% vs 46%, p-0.006; OS: 72% vs 53%, p-0.01)In the multivariate model, the ages of 40 years, LDH-gt;3x, ECOG PS 2 and CNS immersion all indicate poor prognosisMoreover, the prognosis will vary depending on the number of prognosis factors (0, 1, 2-4, the three-year PFS are: 91%, 73%, 50%, and the three-year OS rate is 95%, 77%, 56%, respectively)Overall, in this analysis of actual clinical cases, the results of adult BL patients were a little better than those of clinical trialsIn addition, the patient's underlying condition at the time of diagnosis can predict the patient's prognosis